---
layout: default
title: Mepivacaine
parent: 僅模型預測 (L5)
nav_order: 643
evidence_level: L5
indication_count: 10
---

# Mepivacaine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the provided report template directly (no repo-specific skill applies to this task — it's a one-shot document synthesis from a supplied Evidence Pack JSON). I verified every field pulled below against the JSON before writing it in.

# Mepivacaine: From Local Anesthesia to Gastroduodenitis

## One-Sentence Summary

Mepivacaine is an amide-type local anesthetic; the evidence pack contains no formal Singapore-registered indication for it (0 licenses, not marketed) and no drug-level mechanism-of-action record.
The TxGNN model's top-ranked prediction is **Gastroduodenitis**, with a prediction score of **99.49%**, but currently **0 clinical trials** and **0 publications** support this direction — active PubMed and ClinicalTrials.gov searches for this drug-disease pair both returned zero results.
The evidence pack's own rationale explicitly notes there is no known anti-inflammatory or mucosal-protective mechanism to explain this prediction; it is a model-only signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not on record in the Singapore registry (0 licenses, drug not marketed). Per the evidence pack's own mechanistic descriptions, mepivacaine is an amide-type local anesthetic used for regional/local anesthesia. |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 99.49% |
| Evidence Level | L5 |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Formal mechanism-of-action data for mepivacaine is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on information embedded in the evidence pack's own repurposing rationale (repeated across several predicted-indication entries), mepivacaine is an amide-type local anesthetic that works by blocking voltage-gated Na⁺ channels to suppress neuronal conduction — the standard mechanism for regional/local anesthesia (e.g., dental blocks, peripheral nerve blocks, epidural anesthesia).

Gastroduodenitis is an inflammatory/mucosal condition of the stomach and duodenum. There is no structural or pharmacological overlap between a sodium-channel-blocking local anesthetic and the inflammatory or acid-related pathways typically implicated in gastroduodenitis (e.g., H. pylori infection, mucosal barrier dysfunction, acid hypersecretion). The evidence pack's own rationale for this specific prediction states this directly: mepivacaine has "no known anti-inflammatory or mucosal-protective mechanism" that would explain efficacy in gastroduodenitis, and the prediction is described as arising purely from indirect associations in the TxGNN knowledge graph rather than from any biological or clinical signal.

In short, the high TxGNN score reflects graph-embedding proximity, not mechanistic plausibility. This is corroborated by the complete absence of clinical trials or literature for this specific drug-disease pair (confirmed via active database queries, not just missing data).

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Safety Considerations

Please refer to the package insert for safety information.

*Note: The evidence pack flags a Blocking-severity data gap (DG001) — TFDA/HSA package-insert warnings and contraindications have not yet been retrieved, which means this candidate cannot yet enter the standard S1 safety pre-assessment stage.*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (gastroduodenitis) is supported only by a TxGNN graph-embedding score, with zero clinical trials and zero literature evidence — this is an L5, model-prediction-only signal, and the evidence pack itself notes no mechanistic plausibility for a local anesthetic treating an inflammatory GI condition. Combined with the missing MOA data and the Blocking-severity safety data gap, this candidate does not currently meet the bar to proceed.

**To proceed, the following is needed:**
- Mechanism-of-action data for mepivacaine (DrugBank API query, currently a data gap)
- TFDA/HSA package insert warnings and contraindications (Blocking data gap DG001 — required before any S1 safety pre-assessment)
- Any preclinical or mechanistic rationale connecting sodium-channel blockade to gastroduodenal mucosal/inflammatory pathways, if this indication is to be pursued further
- Consider redirecting research attention to the pack's stronger-evidence signal instead: rank 7, "hypertensive disorder" (L2, 4 clinical trials + 20 publications), though note that evidence there supports acute perioperative/tourniquet-induced hypertension management rather than treatment of essential hypertension — the disease-label match is broader than what the underlying studies actually demonstrate, and this scope mismatch would need to be resolved before any decision upgrade
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

